NWPHF Stock Chart & Stats
$20.00
$0.00(0.00%)
At close: 4:00 PM EDT
$20.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$9.36 - $20.00
Previous CloseN/A
Volume125.00
Average Volume (3M)0.00
Market Cap
$317.99M
Enterprise Value$484.97
Total Cash (Recent Filing)$28.85M
Total Debt (Recent Filing)$38.13M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Sep 22, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding20,805,798
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)-45.95
Price to Sales (P/S)26.73
P/FCF Ratio15.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$54.88Price Target Upside174.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.82
Revenue Forecast (FY)$12.70M
Bulls Say, Bears Say
Bulls Say
Partner Validation And Improved Funding RunwayThe Eisai transaction validates evenamide externally and provides substantial non-dilutive support. Deferred EIB repayments reduce near-term cash pressure, allowing management to fund pivotal development while preserving greater strategic flexibility.
Large Global Pivotal Clinical ProgramA broad, global pivotal program increases the opportunity to generate decisive evidence across treatment-resistant schizophrenia. Multiple studies and defined 2026 readouts create a structured path toward regulatory submission and potential commercialization.
Clinical Efficacy, Safety And Intellectual Property SupportStatistically significant efficacy, low reported attrition and a favorable safety profile strengthen the product case. Additional patent protection could extend the commercial window, supporting durable differentiation and partner interest if pivotal results confirm benefits.
Bears Say
Negative Equity And Substantial LeverageNegative equity limits financial resilience and reduces flexibility during a capital-intensive development phase. Substantial debt creates refinancing exposure, while weaker negotiating conditions could force additional borrowing or equity issuance before products generate dependable cash.
Lumpy Revenue And Recurring LossesThe business remains dependent on episodic licensing and milestone income rather than recurring product revenue. Sharp year-to-year swings and a history of losses make profitability difficult to forecast and leave long-term funding capacity tied to pipeline events.
Trial Execution And Conditional Funding DependenceOperational delays could push out pivotal readouts and regulatory milestones, extending cash needs. Because a meaningful funding tranche depends on positive results, an unfavorable outcome or timing slippage could shorten runway and increase dilution or financing risk.
Newron Pharmaceuticals SpA News
NWPHF FAQ
What was Newron Pharmaceuticals SpA’s price range in the past 12 months?
Newron Pharmaceuticals SpA lowest stock price was $9.36 and its highest was $20.00 in the past 12 months.
What is Newron Pharmaceuticals SpA’s market cap?
Newron Pharmaceuticals SpA’s market cap is $317.99M.
When is Newron Pharmaceuticals SpA’s upcoming earnings report date?
Newron Pharmaceuticals SpA’s upcoming earnings report date is Sep 22, 2026 which is in 23 days.
How were Newron Pharmaceuticals SpA’s earnings last quarter?
Newron Pharmaceuticals SpA released its earnings results on Mar 24, 2026. The company reported -$0.765 earnings per share for the quarter, missing the consensus estimate of -$0.093 by -$0.672.
Is Newron Pharmaceuticals SpA overvalued?
According to Wall Street analysts Newron Pharmaceuticals SpA’s price is currently Undervalued.
Does Newron Pharmaceuticals SpA pay dividends?
Newron Pharmaceuticals SpA does not currently pay dividends.
What is Newron Pharmaceuticals SpA’s EPS estimate?
Newron Pharmaceuticals SpA’s EPS estimate is -0.22.
How many shares outstanding does Newron Pharmaceuticals SpA have?
Newron Pharmaceuticals SpA has 20,805,798 shares outstanding.
What happened to Newron Pharmaceuticals SpA’s price movement after its last earnings report?
Newron Pharmaceuticals SpA reported an EPS of -$0.765 in its last earnings report, missing expectations of -$0.093. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Newron Pharmaceuticals SpA?
Currently, no hedge funds are holding shares in NWPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Newron Pharmaceuticals SpA
Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical enterprise focused on discovering and progressing therapeutic solutions. Its primary areas of research and development encompass conditions affecting the central and peripheral nervous systems, alongside pain management, with activities primarily conducted in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease and is also exploring its application for levodopa-induced dyskinesia. Furthermore, Newron is advancing Evenamide for various forms of schizophrenia, including those resistant to existing treatments, and Ralfinamide for the rare disease indication of neuropathic pain.
NWPHF Stock 12 Month Forecast
Average Price Target
$54.88
▲(174.40% Upside)
Technical Analysis
Addex Therapeutics
―
Molecular Partners AG
―
Idorsia Ltd
―
Santhera Pharmaceuticals Holding
―
MindMaze Therapeutics Holding SA
―
Ownership Overview
― Insiders
0.01% Mutual Funds
0.05% Other Institutional Investors
99.26% Public Companies and
Individual Investors